- Home
- ARQT
as 12-20-2024 4:00pm EST
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $15.50 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.60 - $15.77 | Next Earning Date: | 11-06-2024 |
| Revenue: | $138,708,000 | Revenue Growth: | 182.84% |
| Revenue Growth (this year): | 208.32% | Revenue Growth (next year): | 48.56% |
Stock Insider Trading Activity of Arcutis Biotherapeutics Inc. (ARQT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Welgus Howard G. | ARQT | Director | Dec 2 '24 | Sell | $12.51 | 10,000 | $125,133.00 | 161,944 | |
| Edwards Larry Todd | ARQT | See Remarks | Nov 30 '24 | Buy | $7.11 | 1,093 | $7,766.86 | 137,728 | |
| Burnett Patrick | ARQT | See Remarks | Nov 22 '24 | Sell | $10.14 | 16,023 | $162,514.88 | 128,669 | |
| Matsuda Masaru | ARQT | See Remarks | Nov 18 '24 | Sell | $9.68 | 1,775 | $17,190.34 | 181,373 | |
| Burnett Patrick | ARQT | See Remarks | Nov 14 '24 | Sell | $10.21 | 69,226 | $712,620.61 | 128,669 | |
| Curran Terrie | ARQT | Director | Nov 11 '24 | Sell | $10.85 | 8,687 | $94,238.31 | 10,139 | |
| Matsuda Masaru | ARQT | See Remarks | Nov 4 '24 | Sell | $8.68 | 5,015 | $43,551.26 | 181,373 | |
| Burnett Patrick | ARQT | See Remarks | Nov 4 '24 | Sell | $8.68 | 15,441 | $134,092.73 | 128,669 | |
| Watanabe Todd Franklin | ARQT | See Remarks | Nov 4 '24 | Sell | $8.68 | 13,871 | $120,458.54 | 832,392 | |
| Welgus Howard G. | ARQT | Director | Nov 1 '24 | Sell | $8.65 | 10,000 | $86,541.00 | 161,944 |
Latest Arcutis Biotherapeutics Inc. News
ARQT Breaking Stock News: Dive into ARQT Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
Arcutis Biotherapeutics Submits Supplemental New Drug Application to FDA for Zoryve Cream
GlobeNewswire
6 days ago
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
GlobeNewswire
15 days ago
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
15 days ago
High Growth Tech Stocks To Watch In December 2024
Argus Research
18 days ago
Daily – Vickers Top Buyers & Sellers for 12/04/2024
GlobeNewswire
19 days ago
Arcutis Announces Promotions on Executive Management Team
Zacks
25 days ago
Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect?
Zacks
25 days ago
Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy?
Compare ARQT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARQT Arcutis Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.